Xilio Therapeutics (XLO) Interest Expenses (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Interest Expenses data on file, last reported at $19000.0 in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses fell 67.8% year-over-year to $19000.0; the trailing twelve-month figure through Mar 2026 stood at $19000.0 (down 67.8% YoY), and the FY2025 full-year result was $125.4 million, up 11.48% from the prior year.
• Interest Expenses declined to $19000.0 in Q1 2026, from $27000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $1.3 million in Q4 2022 to a low of $19000.0 in Q1 2026.
• A 5-year average of $261176.5 and a median of $175000.0 in 2024 frame the typical range for Interest Expenses.
• Peak annual rise in Interest Expenses reached 1154.0% in 2022, while the deepest fall reached 98.61% in 2022.
• Tracing XLO's Interest Expenses over 5 years: stood at $1.3 million in 2022, then declined by 13.64% to $1.1 million in 2023, then sank by 73.96% to $282000.0 in 2024, then sank by 90.43% to $27000.0 in 2025, then dropped by 29.63% to $19000.0 in 2026.
• Business Quant data shows XLO's Interest Expenses at $19000.0 in Q1 2026, $27000.0 in Q4 2025, and $68000.0 in Q3 2025.